1. Show article details.

    BRIEF-Xbiotech - Announced That Human Immune Donors Have Been Identified That Can Support Co's Development Of True Human Antibody Therapy For Covid-19

    Reuters – 5:58 PM ET 05/01/2020


  2. Show article details.

    XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy

    GlobeNewswire – 9:25 AM ET 05/01/2020

    Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19 XBiotech Inc. (XBIT) announced today that human immune donors have now been identified that can support the Company’s development of a True Human™ antibody therapy for COVID-19.

  3. Show article details.

    XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)

    GlobeNewswire – 9:15 AM ET 04/14/2020

    XBiotech Inc. (XBIT) announced today that a novel antibody it has discovered that neutralizes interleukin-1 alpha has now been advanced as a product candidate for clinical and commercial development.

  4. Show article details.

    XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

    GlobeNewswire – 4:53 PM ET 04/03/2020

    XBiotech Inc. (XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration investigational program for U.S. blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.

  5. Show article details.

    XBiotech Announces Final Results of Tender Offer

    GlobeNewswire – 8:15 AM ET 02/19/2020

    XBiotech Inc. (XBIT) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.

  6. Show article details.

    Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer

    GlobeNewswire – 1:24 PM ET 02/13/2020

    This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor. XBiotech Announces Preliminary Results of Tender Offer. XBiotech Inc. (XBIT) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.

  7. Show article details.

    XBiotech Announces Preliminary Results of Tender Offer

    GlobeNewswire – 8:15 AM ET 02/13/2020

    XBiotech Inc. (XBIT) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.


Today's and Upcoming Events

  • Aug

    XBIT to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May

    XBIT announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.